Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daiichi Sankyo
Pharma
AZ, Daiichi kick off busy 2025 with FDA nod for their 2nd ADC
The TROP2 ADC also awaits an FDA decision in EGFR-mutated lung cancer and a key readout in first-line non-small cell lung cancer in 2025.
Angus Liu
Jan 17, 2025 9:14pm
Simcere, Takeda and Samsung Biologics—Fierce Pharma Asia
Jan 17, 2025 10:58am
Daiichi, BIOSECURE, Amgen—Fierce Pharma Asia
Dec 13, 2024 8:43am
Daiichi Sankyo builds $152M ADC plant in China
Dec 11, 2024 9:47am
AZ's Enhertu, Akeso's bispecifics win reimbursement in China
Dec 4, 2024 12:52pm
Kelun's Merck-partnered TROP2 ADC snags first nod in China
Nov 27, 2024 10:56am
